Founded in 2018 and based in Boston, Massachusetts, ConcertAI focuses on leveraging artificial intelligence and real-world data to innovate oncology research and care solutions. The company's core mission is to transform how insights are generated and accelerate therapeutic innovations to patients. ConcertAI offers a suite of medical research tools designed for care-based oncology research and data analytics, targeting the biopharma sector to enhance trial data analysis and implement novel data techniques for various types of cancer.
Notable figures associated with ConcertAI include CEO Jeff Elton, who actively promotes equity and trial diversity. The company has formed significant partnerships with organizations like Caris Life Sciences and PathAI to expand its product offerings. ConcertAI's achievements include being chosen by leading biopharma companies for its advanced AI and data technologies, which have had a substantial impact on accelerating clinical trials and improving oncology research outcomes.
